X4 Pharmaceuticals Inc

Healthcare · Biotechnology

2.80$ -0.7% vs. previous close Closing price · As of: Oct 8, 2026

Statements

Balance Sheet

X4 Pharmaceuticals Inc (XFOR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 253 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet XFOR
Line item	Q1 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	–	7.6	11	40	37	81	69	57	46	36	63	134	110	161	154	143	133	123	161	142	121	117	100	81	113	156	124	173	173	147	112	211	178	146	130	105	164	290	270	253
Current Assets	–	5.7	9.1	38	33	80	69	57	45	35	26	97	79	129	122	110	94	83	120	101	81	88	71	53	86	129	98	148	148	122	87	175	143	112	96	73	133	262	242	219
Cash	–	3.0	3.9	33	31	77	64	50	41	31	22	93	76	126	115	104	89	79	115	95	76	82	66	47	80	122	94	137	132	99	60	147	97	56	40	39	70	217	217	195
Cash & Short-Term Investments	–	3.0	3.9	33	31	77	64	50	41	31	22	93	76	126	115	104	89	79	115	95	76	82	66	47	80	122	94	142	142	114	81	169	135	102	87	63	122	253	234	208
Receivables	–	1.3	1.9	2.0	1.5	1.6	1.9	2.2	2.9	2.9	1.6	1.7	1.7	2.0	3.4	0.5	0.6	0.9	0.8	1.1	0.6	0.7	0.9	0.8	0.9	1.2	0.7	0.8	0.4	0.6	0.7	0.9	1.1	1.7	1.2	1.9	1.6	0.6	1.1	2.0
Inventory	–	1.2	–	0.0	5.3	0.4	2.3	0.1	0.1	–	–	3.2	–	–	–	–	–	–	–	–	–	–	–	-0.8	–	–	–	–	–	0.0	–	0.8	2.4	2.8	3.1	3.2	4.1	4.5	4.6	5.5
Property, Plant & Equipment	–	–	–	–	–	0.3	–	–	–	0.2	3.0	2.4	2.5	2.4	2.3	2.1	9.6	9.2	1.8	11	1.6	10	9.7	9.3	1.2	1.1	1.0	0.9	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	–	–	–	–	–	–	–	–	27	27	27	27	27	27	27	27	27	27	27	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17
Intangible Assets	–	–	–	–	–	–	–	–	–	–	4.9	4.9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	10	10	10	9.8	9.6	9.4	9.3	9.1	13
Total Liabilities	–	64	33	21	26	23	21	19	18	14	33	37	30	31	35	38	43	50	54	52	52	53	50	51	52	82	73	106	106	96	111	116	119	124	107	101	102	104	102	98
Current Liabilities	–	12	21	8.8	13	11	9.3	10	8.9	5.4	16	13	8.3	9.4	8.0	11	13	12	15	13	13	14	15	22	29	22	19	22	25	23	24	29	29	33	26	23	24	26	24	19
Short-Term Debt	–	5.2	10	2.3	2.3	2.3	2.3	3.5	2.9	1.7	6.1	5.0	0.9	0.9	0.9	0.9	0.8	0.8	0.9	1.0	1.7	1.9	4.5	9.7	16	2.5	1.7	1.9	1.1	1.1	1.1	1.2	1.2	1.3	1.3	1.4	1.2	1.0	0.7	0.5
Accounts Payable	–	1.6	–	–	4.2	1.9	1.1	2.1	2.1	0.5	6.1	3.1	1.7	2.1	1.2	1.8	3.9	3.1	3.1	2.5	2.4	4.3	3.6	3.7	3.8	7.8	6.0	5.1	8.1	8.9	8.9	8.0	8.6	8.6	11	7.7	5.1	5.7	5.1	3.9
Long-Term Debt	–	–	–	–	–	4.4	–	–	–	8.1	13	22	20	20	25	25	26	33	33	34	33	33	30	24	19	32	32	32	54	55	55	75	75	75	76	76	76	76	77	77
Shareholders' Equity	–	-57	-22	18	12	59	48	38	28	22	29	96	79	129	119	105	90	73	107	89	69	64	50	30	62	74	52	68	68	51	1.0	94	60	22	23	4.0	62	186	168	155
Retained Earnings	–	-58	-64	-69	-81	-92	-103	-115	-126	-135	-90	-103	-121	-132	-143	-158	-176	-194	-213	-232	-253	-283	-305	-326	-348	-377	-401	-456	-459	-478	-530	-439	-476	-515	-515	-541	-571	-595	-615	-631
Shares Outstanding	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.1	0.4	0.5	0.5	0.7	0.7	0.7	0.7	0.7	0.9	0.9	1.0	1.1	1.2	2.8	3.4	4.9	5.6	6.6	6.6	6.7	6.7	6.7	6.8	6.9	7.4	43	111	126	126

Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings